Kitov Pharmaceuticals Holdings Ltd (KTOV) Receives Consensus Recommendation of “Strong Buy” from Analysts
Shares of Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokers have set a 12-month consensus price target of $7.00 for the company and are forecasting that the company will post ($0.29) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Kitov Pharmaceuticals Holdings an industry rank of 108 out of 265 based on the ratings given to its competitors.
KTOV has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Kitov Pharmaceuticals Holdings from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research report on Wednesday, July 13th. Rodman & Renshaw reissued a “buy” rating on shares of Kitov Pharmaceuticals Holdings in a research report on Monday, July 11th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/kitov-pharmaceuticals-holdings-ltd-ktov-receives-consensus-recommendation-of-strong-buy-from-analysts.html
A hedge fund recently bought a new stake in Kitov Pharmaceuticals Holdings stock. Sabby Management LLC bought a new position in shares of Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 232,524 shares of the company’s stock, valued at approximately $725,000. Sabby Management LLC owned 5.96% of Kitov Pharmaceuticals Holdings as of its most recent filing with the SEC.
Shares of Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) traded up 0.56% during midday trading on Tuesday, hitting $3.61. 74,617 shares of the stock were exchanged. The firm has a 50 day moving average of $3.38 and a 200 day moving average of $4.04. Kitov Pharmaceuticals Holdings has a 12-month low of $2.20 and a 12-month high of $6.95. The firm’s market cap is $27.66 million.
About Kitov Pharmaceuticals Holdings
Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kitov Pharmaceuticals Holdings Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals Holdings Ltd and related companies with MarketBeat.com's FREE daily email newsletter.